Becton Dickinson stock has delivered a 19.2% return over the past year, and the latest valuation work using a Discounted Cash Flow (DCF) intrinsic value estimate suggests the shares may still trade below that estimate by around 24.4%. At the same time, broad valuation checks point to a more mixed picture and standard earnings multiples look closer to fair value than outright cheap.

• Becton Dickinson’s 19.2% one year gain puts recent shareholders in profit, which raises the question of how much upside is left from here.
• The recent news flow around higher revenue expectations can support the intrinsic value case, while any disappointment on future earnings delivery or cash generation may pressure that valuation.
• The company scores 4 out of 6 on broader valuation checks, which is a mixed picture rather than a clear bargain or clear overvaluation, and you can see the details at 4 out of 6.

The issue now is whether Becton Dickinson’s current share price already reflects this improved outlook or if the intrinsic value estimate still points to meaningful upside.

Is Becton Dickinson Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Becton Dickinson is worth based on the cash it can generate for shareholders. The latest twelve month free cash flow sits at about $2.48b, and the model assumes these cash flows keep growing rather than shrinking over time. On that basis, the intrinsic value comes out at about $234 per share.

Compared with the current share price, this implies Becton Dickinson trades at roughly a 24.4% discount to that intrinsic value. This points to the stock looking undervalued on cash flow assumptions alone. Because Becton, Dickinson and Company recently raised its full year 2026 revenue and earnings guidance after reporting stronger Q3 results, the upgraded outlook helps explain why the cash flow based value sits above where the market is pricing the shares today.

Taking the DCF output at face value, Becton Dickinson stock currently screens as undervalued.

Our Discounted Cash Flow (DCF) analysis suggests Becton Dickinson is undervalued by 24.4%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Does Becton Dickinson Look Fairly Valued on Earnings?

The P/E ratio suits Becton Dickinson because earnings remain a key focus for many healthcare investors. The stock currently trades on a P/E of about 29.2x, which sits above the Medical Equipment industry average of roughly 26.1x but below the peer group average of about 32.4x.

A tailored fair P/E for Becton Dickinson of around 30.7x reflects its sector, profit profile and risk, and is only slightly above where the stock trades today. That small gap suggests the market is pricing the shares in line with what would be expected for a large, established medical equipment company, rather than offering a clear discount or demanding a heavy premium.

On the P/E multiple, Becton Dickinson stock currently looks roughly fairly valued.

The Becton Dickinson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Becton Dickinson sit between the mixed valuation signals above and the real world assumptions that need to hold for the stock to be worth materially more or less than today’s price. Each narrative connects Becton Dickinson's possible growth, margins and earnings path with a clear fair value view, tied to specific potential catalysts and risks, so you can track which story appears to be unfolding over time on the Community page.

The Becton Dickinson community sits on two very different stories, with some seeing execution and capital returns as support for upside while others focus on utilization and inflation risks.

Bull case: 7% undervalued

"The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio, enabling higher cash flow predictability and margin improvement..."

Bear case: 10% overvalued

"Heightened global healthcare cost-containment efforts and increasing preference for low-cost suppliers threaten Becton Dickinson's ability to maintain pricing power and margin stability, resulting in possible compression of both gross and net margins..."

Do you think there's more to the story for Becton Dickinson? Head over to our Community to see what others are saying!

The Bottom Line

Becton Dickinson looks undervalued on the Discounted Cash Flow (DCF) intrinsic value estimate, while the P/E based view suggests the stock trades around what the market usually pays for similar healthcare companies. That split reflects different sensitivities, with the intrinsic value view hinging on how reliably future cash flows materialise and the multiple view driven more by sentiment and peer expectations. The key question from here is whether Becton Dickinson can deliver on its revenue and earnings guidance without margin slippage, which would help show whether the current discount is an opportunity or a fair reflection of execution and cost risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.